Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Dose-escalation Phase I/IIa Trial With Controlled Human Malaria Infection to Evaluate Safety, Tolerability, Immunogenicity and Efficacy of an Investigational RNA-based Vaccine for Prevention of P. Falciparum Malaria in Healthy Malaria naïve Adults

NCT06069544 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT06069544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06069544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Dose-escalation Phase I/IIa Trial With Controlled Human Malaria Infection to Evaluate Safety, Tolerability, Immunogenicity and Efficacy of an Investigational RNA-based Vaccine for Prevention of P. Falciparum Malaria in Healthy Malaria naïve Adults
Lead sponsor
BioNTech SE
Phase
Phase 1/2
Overall status
Completed
Start date
November 13, 2023
Completion date
March 20, 2026
Enrollment
163 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

malaria